Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
10.04
+1.58 (18.68%)
At close: Oct 10, 2025, 4:00 PM EDT
9.82
-0.22 (-2.19%)
After-hours: Oct 10, 2025, 7:59 PM EDT
Monte Rosa Therapeutics Revenue
Monte Rosa Therapeutics had revenue of $23.19M in the quarter ending June 30, 2025, with 394.01% growth. This brings the company's revenue in the last twelve months to $177.99M. In the year 2024, Monte Rosa Therapeutics had annual revenue of $75.62M.
Revenue (ttm)
$177.99M
Revenue Growth
+2,990.57%
P/S Ratio
4.63
Revenue / Employee
$1,328,254
Employees
134
Market Cap
620.06M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 75.62M | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
GLUE News
- 23 days ago - Monte Rosa: H1 2026 NEK7 Protein Degrader MRT-8102 Data Could Be Added POC - Seeking Alpha
- 25 days ago - Monte Rosa Therapeutics And The Promise Of Molecular Glue Degraders - Seeking Alpha
- 27 days ago - Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases - GlobeNewsWire
- 5 weeks ago - Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - GlobeNewsWire
- 3 months ago - Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines - GlobeNewsWire
- 4 months ago - Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - GlobeNewsWire